DK0804417T3 - Fremgangsmåde til racemisering til brug ved fremstilling af levobupivacain og beslægtede piperidincarboxanilid bedøvelsesmidler - Google Patents

Fremgangsmåde til racemisering til brug ved fremstilling af levobupivacain og beslægtede piperidincarboxanilid bedøvelsesmidler

Info

Publication number
DK0804417T3
DK0804417T3 DK96900349T DK96900349T DK0804417T3 DK 0804417 T3 DK0804417 T3 DK 0804417T3 DK 96900349 T DK96900349 T DK 96900349T DK 96900349 T DK96900349 T DK 96900349T DK 0804417 T3 DK0804417 T3 DK 0804417T3
Authority
DK
Denmark
Prior art keywords
levobupivacaine
racemization
anesthetics
preparation
carboxanilide
Prior art date
Application number
DK96900349T
Other languages
English (en)
Inventor
Ulrich Conrad Chiroscienc Dyer
Marianne Chiroscience Langston
Martin Chiroscience Limi Woods
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of DK0804417T3 publication Critical patent/DK0804417T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Rolling Contact Bearings (AREA)
  • Optical Head (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK96900349T 1995-01-18 1996-01-12 Fremgangsmåde til racemisering til brug ved fremstilling af levobupivacain og beslægtede piperidincarboxanilid bedøvelsesmidler DK0804417T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501071.6A GB9501071D0 (en) 1995-01-18 1995-01-18 Racemisation
PCT/GB1996/000067 WO1996022281A1 (en) 1995-01-18 1996-01-12 Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents

Publications (1)

Publication Number Publication Date
DK0804417T3 true DK0804417T3 (da) 2003-10-06

Family

ID=10768271

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96900349T DK0804417T3 (da) 1995-01-18 1996-01-12 Fremgangsmåde til racemisering til brug ved fremstilling af levobupivacain og beslægtede piperidincarboxanilid bedøvelsesmidler

Country Status (20)

Country Link
EP (1) EP0804417B1 (da)
JP (1) JP4015696B2 (da)
KR (1) KR100404390B1 (da)
CN (1) CN1172912C (da)
AT (1) ATE242214T1 (da)
AU (1) AU701221B2 (da)
BR (1) BR9606821A (da)
CA (1) CA2208522C (da)
DE (1) DE69628540T2 (da)
DK (1) DK0804417T3 (da)
ES (1) ES2201166T3 (da)
FI (1) FI117437B (da)
GB (1) GB9501071D0 (da)
HU (1) HU227426B1 (da)
MX (1) MX9705428A (da)
NO (1) NO308843B1 (da)
PL (1) PL184091B1 (da)
PT (1) PT804417E (da)
WO (1) WO1996022281A1 (da)
ZA (1) ZA96403B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0002246A (pt) 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
EP3103477A1 (en) 2004-09-17 2016-12-14 Durect Corporation Sustained local anesthetic composition containing saib
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
PL2117521T3 (pl) 2006-11-03 2012-11-30 Durect Corp Transdermalne systemy dostarczania zawierające bupiwakainę
EP3326621A1 (en) 2007-12-06 2018-05-30 Durect Corporation Oral pharmaceutical dosage forms
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN102093284B (zh) * 2010-12-29 2013-05-08 宜昌人福药业有限责任公司 富集哌啶-2-甲酰苯胺类旋光化合物的方法
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
CN106187864B (zh) * 2016-07-11 2018-11-23 江苏天和制药有限公司 一种由盐酸布比卡因制备高纯度布比卡因碱的方法
EP4090353A4 (en) 2020-01-13 2023-08-09 Durect Corporation DELAYED-RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED PROCEDURES
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法
WO2023158722A2 (en) * 2022-02-16 2023-08-24 Teva Pharmaceuticals International Gmbh Processes for preparation of avacopan and intermediates thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2301498A1 (fr) * 1975-02-20 1976-09-17 Maggioni & C Spa Methode pour la racemisation d'une lysine optiquement active

Also Published As

Publication number Publication date
GB9501071D0 (en) 1995-03-08
FI973040A0 (fi) 1997-07-17
ATE242214T1 (de) 2003-06-15
PL321378A1 (en) 1997-12-08
EP0804417B1 (en) 2003-06-04
HUP9901418A2 (hu) 1999-08-30
ES2201166T3 (es) 2004-03-16
MX9705428A (es) 1997-11-29
DE69628540T2 (de) 2004-01-08
FI117437B (fi) 2006-10-13
BR9606821A (pt) 1997-12-23
CA2208522A1 (en) 1996-07-25
NO973312L (no) 1997-07-17
EP0804417A1 (en) 1997-11-05
FI973040L (fi) 1997-07-17
CN1168134A (zh) 1997-12-17
CN1172912C (zh) 2004-10-27
PT804417E (pt) 2003-09-30
KR100404390B1 (ko) 2004-01-31
AU4394896A (en) 1996-08-07
HU227426B1 (en) 2011-05-30
ZA96403B (en) 1997-01-20
JPH11501905A (ja) 1999-02-16
DE69628540D1 (de) 2003-07-10
HUP9901418A3 (en) 2001-01-29
AU701221B2 (en) 1999-01-21
WO1996022281A1 (en) 1996-07-25
PL184091B1 (pl) 2002-08-30
JP4015696B2 (ja) 2007-11-28
CA2208522C (en) 2007-03-13
NO308843B1 (no) 2000-11-06
KR19980701432A (ko) 1998-05-15
NO973312D0 (no) 1997-07-17

Similar Documents

Publication Publication Date Title
DK0804417T3 (da) Fremgangsmåde til racemisering til brug ved fremstilling af levobupivacain og beslægtede piperidincarboxanilid bedøvelsesmidler
DE69637726D1 (de) Gruppen zum einfangen von nukleinsäuren
DE69531624D1 (de) Verfahren zur herstellung von levobupivacaine und analoge
EP0636879A3 (en) Biosensor and method for its manufacture.
DE69942068D1 (de) Erzeugen eines nichtlinearen modells und erzeugen tzung desselben
NO308074B1 (no) FremgangsmÕte for racemisering av optiske anrikete heterocykliske karboksanilider
DK0879228T3 (da) Fremgangsmåde til fremstilling af d-threo-(R,R)-methylphenidat og recirkulering af uønskede enantiomerer ved epimerisering
HUT77631A (hu) Eljárás a levobupivakain és származékai rezolválására
ATE221533T1 (de) Verfahren zur racematspaltung von etodolac unter verwendung von glucamin-derivaten
CY1107104T1 (el) Διαδικασια για την παρασκευη (r)-g(a)-(2,3-διμεθοξυφαινυλο)-1-(2-(4-φθοροφαινυλο)-αιθυλο)-4- πιπεριδινομεθανολη
ATE497545T1 (de) Oligonukleotide zur detektion von salmonella
DE59604829D1 (de) Kontinuierliches Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethylpiperidin
ATE194602T1 (de) Verfahren zur herstellung von 1,4,7,10- tetraazacyclododecan und dessen derivaten
DK0914605T3 (da) Molekylemodel for VLA-4-inhibitorer
ATE213782T1 (de) Verfahren zur biotransformation von colchicinoid- verbindungen in die entsprechenden 3- glycosylderivate
NO975961L (no) Fremgangsmåte for fremstilling av 1-(3-trialkylsilylfenyl)-2,2,2-trifluorometyl-ethanonderivater
ES2138734T3 (es) Procedimiento para la preparacion de derivados de 1-(3-trialquilsililfenil)-2,2,2-trifluormetil etanona.
AU7377296A (en) Method for treating hepatitis virus infection
DE60104822D1 (de) Pseudopolymorph von (-)-cis-2-(2-chlorphenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-on hydrochlorid
NO972129L (no) Fremgangsmåte for fremstilling av 1-halo-3-trialkylsilanyl-benzenderivater
ATE212969T1 (de) Verfahren zur herstellung von 2-halogenindan-1- onen
DK0819117T3 (da) Dimethylaminbenzoat- eller -p-anisatkatalyseret fremgangsmåde til fremstilling af 4-(nitrophenyl)dihydropyridiner
DE59700961D1 (de) Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethylpiperidin (TAD) über das Zwischenprodukt 2,2,6,6-Tetramethyl-4-[(2,2,6,6-tetramethyl-4-piperidyliden)amino]-piperidin
ATE421953T1 (de) Verfahren zur racemisierung von 1-benzyl-4-(4- fluorophenyl)-3-hydroxymethyl-1,2,3,6- tetrahydropyridin und dessen verwendung in der synthese von paroxetin